Almost all medical specialities utilise cross-sectional imaging of the abdomen to evaluate many different medical conditions. This ever-increasing use of cross-sectional imaging has led to a dramatic increase in the detection rate of adrenal nodules. Following appropriate biochemical and radiological evaluation, the vast majority of these are shown to be benign adrenal adenomas. A small minority are diagnosed with a functional or malignant lesion that may result in significant morbidity and mortality requiring specialist management.
FassnachtMArltWBancosIet al. Management of adrenal incidentalomas: European society of endocrinology clinical practice guideline in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol2016; 175: G1–G34.
3.
FarrugiaFAMartikosGTzanetisPet al. Pheochromocytoma, diagnosis and treatment: review of the literature. Endocr Regul2017; 51: 168–81.
4.
NiemanLBillerBFindlingJet al. The diagnosis of Cushing’s syndrome: an endocrine society clinical practice guideline. Eur J Endocrinol. Epub ahead of print 18August2009. DOI: 10.1530/eje-09-0695.
5.
DennedyMCAnnamalaiAKPrankerd-SmithOet al. Low DHEAS: a sensitive and specific test for the detection of subclinical hypercortisolism in adrenal incidentalomas. J Clin Endocrinol Metab2017; 102: 786–92.
6.
LamKYLoCY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching hospital. Clin Endocrinol2002; 56: 95–101.
FunderJWCareyRMManteroFet al. The management of primary aldosteronism: case detection, diagnosis, and treatment: an endocrine society clinical practice guideline. J Clin Endocrinol Metab2016; 101: 1889–916.
9.
BancosIPreteA. Approach to the patient with adrenal incidentaloma. J Clin Endocrinol Metab2021; 106: 3331–53.
10.
SahinMKebapcilarLTaslipinarAet al. Comparison of 1 mg and 2 mg overnight dexamethasone suppression tests for the screening of Cushing’s syndrome in obese patients. Intern Med2009; 48: 33–9.
11.
Araujo-CastroMValderrábanoPEscobar-MorrealeHFet al. Urine steroid profile as a new promising tool for the evaluation of adrenal tumors. Literature review. Endocrine2021; 72: 40–8.
12.
BancosITaylorAEChortisVet al. Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study. Lancet Diabetes Endocrinol2020; 8: 773–81.
13.
Mayo-SmithWWSongJHBolandGLet al. Management of incidental adrenal masses: a white paper of the ACR incidental findings committee. J Am Coll Radiol2017; 14: 1038–44.
14.
SzolarDKorobkinMReittnerPet al. Adrenocortical carcinomas and adrenal pheochromocytomas: mass and enhancement loss evaluation at delayed contrast-enhanced CT1. Radiology2005; 234: 479–85.
15.
BaratMCottereauASGaujouxSet al. Adrenal mass characterization in the era of quantitative imaging: state of the art. Cancers2022; 14: 1–20.
16.
DinnesJBancosIDi RuffanoLFet al. Management of endocrine disease: imaging for the diagnosis of malignancy in incidentally discovered adrenal masses: a systematic review and meta-analysis. Eur J Endocrinol2016; 175: R51–R64.
17.
GrumbachMMBillerBMKBraunsteinGDet al. Management of the Clinically Inapparent Adrenal Mass (“Incidentaloma”). Ann Intern Med 2003; 138: 424–429.
18.
KahramangilBKoseERemerEMet al. A modern assessment of cancer risk in adrenal incidentalomas analysis of 2219 patients. Ann Surg2022; 275: E238–44.
19.
CanuLVan HemertJAWKerstensMNet al. CT characteristics of pheochromocytoma: relevance for the evaluation of adrenal incidentaloma. J Clin Endocrinol Metab2019; 104: 312–8.
20.
DecmannÁPergePTóthMet al. Adrenal myelolipoma: a comprehensive review. Endocrine2018; 59: 7–15.
ElhassanYSAlahdabFPreteAet al. Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess a systematic review and meta-analysis. Ann Intern Med2019; 171: 107–16.